KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.
Follow KALA
KALA BIO, Inc. (KALA) EV/Sales
As of 16 October 2026, KALA BIO, Inc. (KALA) trades at a EV/Sales of 7.5×. Over the past ten years it has ranged from −0.8× (November 2023) to 112× (July 2020); the current reading is higher than 65% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 5.2× | (27.52%) |
| FY2021 | 7.2× | (83.43%) |
| FY2020 | 43.4× | 132.43% |
| FY2019 | 18.7× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2022 | 2.6× | (66.93%) |
| Jun 2022 | 7.7× | (39.97%) |
| Mar 2022 | 12.9× | 78.99% |
| Dec 2021 | 7.2× | (34.75%) |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. compare | −3.3× |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| IOBTQ IO Biotech, Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| UNBX UNITY Biotechnology, Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | 6.2× |
| KALA KALA BIO, Inc. | 7.5× |
| ERNA Ernexa Therapeutics Inc. compare | 51.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)